Last reviewed · How we verify
Oxytocin bolus or oxytocin infusion
Oxytocin binds to oxytocin receptors on uterine smooth muscle and mammary gland tissue to stimulate contractions and milk ejection.
Oxytocin binds to oxytocin receptors on uterine smooth muscle and mammary gland tissue to stimulate contractions and milk ejection. Used for Labor induction, Labor augmentation, Postpartum hemorrhage prevention and treatment.
At a glance
| Generic name | Oxytocin bolus or oxytocin infusion |
|---|---|
| Sponsor | Stony Brook University |
| Drug class | Oxytocin receptor agonist |
| Target | Oxytocin receptor (OXTR) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Oxytocin is a neurohypophyseal hormone that acts as an agonist at oxytocin receptors, G-protein coupled receptors present on myometrial cells and lacteal tissue. Receptor activation triggers calcium influx and smooth muscle contraction, facilitating labor progression and milk letdown. Both bolus and infusion formulations are used clinically to induce or augment labor and manage postpartum hemorrhage.
Approved indications
- Labor induction
- Labor augmentation
- Postpartum hemorrhage prevention and treatment
- Incomplete or inevitable abortion
Common side effects
- Uterine hyperstimulation
- Maternal hypertension
- Nausea and vomiting
- Fetal bradycardia
- Water intoxication (with prolonged infusion)
- Headache
Key clinical trials
- Comparing Tranexamic Acid Versus Ecbolics in Preventing Hemorrhage During and After Cesarean Section (NA)
- Oxytocin Bolus Versus Infusion in Elective Cesarean Section" (PHASE4)
- A Trial of Sublingual Misoprostol to Reduce Primary Postpartum Haemorrhage After Vaginal Delivery (PHASE4)
- Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress (NA)
- Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women (PHASE1)
- Oxytocin And Uterotonic Agent Use For Cesarean Delivery (PHASE4)
- A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (PHASE1)
- Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum Hemorrhage (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxytocin bolus or oxytocin infusion CI brief — competitive landscape report
- Oxytocin bolus or oxytocin infusion updates RSS · CI watch RSS
- Stony Brook University portfolio CI